- Home
- HNRG vs CTNM Comparison
HNRG vs CTNM Comparison
Compare HNRG & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNRG
- CTNM
- Stock Information
- Founded
- HNRG 1949
- CTNM 2009
- Country
- HNRG United States
- CTNM United States
- Employees
- HNRG N/A
- CTNM N/A
- Industry
- HNRG Coal Mining
- CTNM
- Sector
- HNRG Energy
- CTNM
- Exchange
- HNRG Nasdaq
- CTNM Nasdaq
- Market Cap
- HNRG 432.4M
- CTNM 453.0M
- IPO Year
- HNRG N/A
- CTNM 2024
- Fundamental
- Price
- HNRG $12.91
- CTNM $14.34
- Analyst Decision
- HNRG Strong Buy
- CTNM Strong Buy
- Analyst Count
- HNRG 1
- CTNM 4
- Target Price
- HNRG $13.00
- CTNM $29.25
- AVG Volume (30 Days)
- HNRG 737.7K
- CTNM 78.5K
- Earning Date
- HNRG 11-12-2024
- CTNM 11-06-2024
- Dividend Yield
- HNRG N/A
- CTNM N/A
- EPS Growth
- HNRG N/A
- CTNM N/A
- EPS
- HNRG N/A
- CTNM N/A
- Revenue
- HNRG $429,359,000.00
- CTNM N/A
- Revenue This Year
- HNRG N/A
- CTNM N/A
- Revenue Next Year
- HNRG $20.84
- CTNM N/A
- P/E Ratio
- HNRG N/A
- CTNM N/A
- Revenue Growth
- HNRG N/A
- CTNM N/A
- 52 Week Low
- HNRG $4.33
- CTNM $12.33
- 52 Week High
- HNRG $13.57
- CTNM $22.00
- Technical
- Relative Strength Index (RSI)
- HNRG 67.09
- CTNM N/A
- Support Level
- HNRG $12.37
- CTNM N/A
- Resistance Level
- HNRG $13.56
- CTNM N/A
- Average True Range (ATR)
- HNRG 0.91
- CTNM 0.00
- MACD
- HNRG 0.18
- CTNM 0.00
- Stochastic Oscillator
- HNRG 88.03
- CTNM 0.00
About HNRG Hallador Energy Company
Hallador Energy Co is a coal mining company with operations in Indiana, USA, and it is part of the electric power generation industry. The operations of the company are divided into two primary reportable segments, the Coal Operations and Electric Operations segments. The majority of revenue is earned from the Coal Operations segment.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.